Phase II Trial of Pyrazoloacridine in Advanced Non-Small Cell Carcinoma of the Lung: A Kansas Cancer...
Phase II Trial of Pyrazoloacridine in Advanced Non-Small Cell Carcinoma of the Lung: A Kansas Cancer Institute and Thompson Cancer Survival Center Study
About this item
Full title
Author / Creator
Publisher
United States: Springer Nature B.V
Journal title
Language
English
Formats
Publication information
Publisher
United States: Springer Nature B.V
Subjects
More information
Scope and Contents
Contents
More active agents are needed in the treatment of metastatic non-small cell lung cancer. Pyrazoloacridine (PZA) is a 9-methoxy acridine compound containing a reducible 5-nitro substituent. Although the mechanism of action of PZA is unknown, the acridine compounds are known to cause cytotoxicity by interaction with DNA and RNA.
Eighteen patients...
Alternative Titles
Full title
Phase II Trial of Pyrazoloacridine in Advanced Non-Small Cell Carcinoma of the Lung: A Kansas Cancer Institute and Thompson Cancer Survival Center Study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_216514135
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_216514135
Other Identifiers
ISSN
0167-6997
E-ISSN
1573-0646
DOI
10.1023/A:1016293527755
